pCPA Update as of June 30, 2017

The latest update as of June 30, 2017 has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO update are as follows:

Six new drug products have initiated pCPA negotiations since the last update, for a total of 42 active negotiations

Seven negotiations have been completed since the last update, for a total of 160 joint negotiations.

No new drug products were added to the “No pCPA Negotiations” list

In addition to the information above, MORSE Consulting is tracking the number of products reviewed by CADTH that have yet to initiate negotiations with the pCPA – which we refer to as “under pCPA Consideration”. The latest update since May 30th, 2017 is:

Three new drug products have received recent CDEC or pERC recommendations, for a total of approximately 24 products under pCPA Consideration

Please see below for more details.

Six new drug products have initiated pCPA negotiations since the last update, for a total of 42 active negotiations